150 related articles for article (PubMed ID: 6132341)
1. Correlations between different measures of antiserotonin activity of drugs. Study with neuroleptics and serotonin receptor blockers.
Ortmann R; Bischoff S; Radeke E; Buech O; Delini-Stula A
Naunyn Schmiedebergs Arch Pharmacol; 1982 Dec; 321(4):265-70. PubMed ID: 6132341
[TBL] [Abstract][Full Text] [Related]
2. The citalopram/5-HTP-induced head shake syndrome is correlated to 5-HT2 receptor affinity and also influenced by other transmitters.
Arnt J; Hyttel J; Larsen JJ
Acta Pharmacol Toxicol (Copenh); 1984 Nov; 55(5):363-72. PubMed ID: 6152104
[TBL] [Abstract][Full Text] [Related]
3. L-5-HTP facilitates the electrically stimulated flexor reflex in pithed rats: evidence for 5-HT2-receptor mediation.
Skarsfeldt T; Arnt J; Hyttel J
Eur J Pharmacol; 1990 Feb; 176(2):135-42. PubMed ID: 1968846
[TBL] [Abstract][Full Text] [Related]
4. Interaction of the D1 receptor antagonist SCH 23390 with the central 5-HT system: radioligand binding studies, measurements of biochemical parameters and effects on L-5-HTP syndrome.
Bischoff S; Heinrich M; Krauss J; Sills MA; Williams M; Vassout A
J Recept Res; 1988; 8(1-4):107-20. PubMed ID: 3290470
[TBL] [Abstract][Full Text] [Related]
5. Effects of 5-HT receptor subtype-selective drugs on locomotor activity and motor habituation in the DHT adult rat model.
Pranzatelli MR; Jappay E; Snodgrass SR
Pharmacol Biochem Behav; 1987 Jul; 27(3):497-504. PubMed ID: 3116560
[TBL] [Abstract][Full Text] [Related]
6. Mediation of ACTH and prolactin responses to 5-HTP by 5-HT2 receptors.
Gartside SE; Cowen PJ
Eur J Pharmacol; 1990 Apr; 179(1-2):103-9. PubMed ID: 2163847
[TBL] [Abstract][Full Text] [Related]
7. Interactions of beta-adrenoceptor agonists and antagonists with the 5-hydroxytryptamine2 (5-HT2) receptor.
Green AR; Johnson P; Nimgaonkar VL
Neuropharmacology; 1983 May; 22(5):657-60. PubMed ID: 6136009
[TBL] [Abstract][Full Text] [Related]
8. The influence of neuroleptics on the behavioural effect of 5-hydroxytryptophan.
Maj J; Baran L; Bigajska K; Rogóz Z; Skuza G
Pol J Pharmacol Pharm; 1978; 30(4):431-40. PubMed ID: 33367
[TBL] [Abstract][Full Text] [Related]
9. Antipsychotic drug effects on dopamine and serotonin receptors: in vitro binding and in vivo turnover studies.
Bacopoulos NG
J Pharmacol Exp Ther; 1981 Dec; 219(3):708-14. PubMed ID: 6170752
[TBL] [Abstract][Full Text] [Related]
10. The D-1 dopamine receptor antagonist SCH 23390 also interacts potently with brain serotonin (5-HT2) receptors.
Bischoff S; Heinrich M; Sonntag JM; Krauss J
Eur J Pharmacol; 1986 Oct; 129(3):367-70. PubMed ID: 3536532
[TBL] [Abstract][Full Text] [Related]
11. The effects of 5-HT uptake- and MAO-inhibitors on L-5-HTP-induced excitation in rats.
Ortmann R; Waldmeier PC; Radeke E; Felner A; Delini-Stula A
Naunyn Schmiedebergs Arch Pharmacol; 1980 Mar; 311(2):185-92. PubMed ID: 6966764
[TBL] [Abstract][Full Text] [Related]
12. The 5-HT syndrome and the drug discrimination paradigm in rats: application in behavioral studies on the central 5-HT system.
Ortmann R
Pharmacopsychiatry; 1985 Mar; 18(2):198-201. PubMed ID: 3875109
[TBL] [Abstract][Full Text] [Related]
13. DuP 734 [1-(cyclopropylmethyl)-4-(2'(4''-fluorophenyl)-2'-oxoethyl)- piperidine HBr], a sigma and 5-hydroxytryptamine2 receptor antagonist: receptor-binding, electrophysiological and neuropharmacological profiles.
Tam SW; Steinfels GF; Gilligan PJ; Schmidt WK; Cook L
J Pharmacol Exp Ther; 1992 Dec; 263(3):1167-74. PubMed ID: 1361572
[TBL] [Abstract][Full Text] [Related]
14. Identity of inhibitory presynaptic 5-hydroxytryptamine (5-HT) autoreceptors in the rat brain cortex with 5-HT1B binding sites.
Engel G; Göthert M; Hoyer D; Schlicker E; Hillenbrand K
Naunyn Schmiedebergs Arch Pharmacol; 1986 Jan; 332(1):1-7. PubMed ID: 2936965
[TBL] [Abstract][Full Text] [Related]
15. Effect of chronic treatment with 5-hydroxytryptophan on cortical serotonin receptors in the rat.
Pranzatelli MR
Clin Neuropharmacol; 1988 Jun; 11(3):257-62. PubMed ID: 3261199
[TBL] [Abstract][Full Text] [Related]
16. Studies with new ergoline derivatives on the effects of central and peripheral 5-hydroxytryptamine receptors.
Harhammer R; Schäfer U; Ott T
Arzneimittelforschung; 1992 Oct; 42(10):1175-9. PubMed ID: 1472137
[TBL] [Abstract][Full Text] [Related]
17. Rodent data and general hypothesis: antipsychotic action exerted through 5-Ht2A receptor antagonism is dependent on increased serotonergic tone.
Martin P; Waters N; Schmidt CJ; Carlsson A; Carlsson ML
J Neural Transm (Vienna); 1998; 105(4-5):365-96. PubMed ID: 9720968
[TBL] [Abstract][Full Text] [Related]
18. Discriminative stimulus properties of quipazine: mediation by serotonin2 binding sites.
Friedman RL; Barrett RJ; Sanders-Bush E
J Pharmacol Exp Ther; 1984 Mar; 228(3):628-35. PubMed ID: 6707913
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the pharmacological characteristics of 5 HT1 and 5 HT2 binding sites with those of serotonin autoreceptors which modulate serotonin release.
Martin LL; Sanders-Bush E
Naunyn Schmiedebergs Arch Pharmacol; 1982 Dec; 321(3):165-70. PubMed ID: 7155196
[TBL] [Abstract][Full Text] [Related]
20. Differential actions of serotonin antagonists on two behavioral models of serotonin receptor activation in the rat.
Lucki I; Nobler MS; Frazer A
J Pharmacol Exp Ther; 1984 Jan; 228(1):133-9. PubMed ID: 6694097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
